Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
BSLN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF36.75 - CHF55.20
Previous CloseN/A
Volume30.09K
Average Volume (3M)45.41K
Market Cap
CHF663.60M
Enterprise ValueCHF643.83M
Total Cash (Recent Filing)CHF120.71M
Total Debt (Recent Filing)CHF111.67M
Price to Earnings (P/E)8.5
Beta0.98
Next Earnings
Aug 19, 2025EPS Estimate
2.03Last Dividend Ex-Date
Apr 11, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)4.70
Shares Outstanding13,314,145
10 Day Avg. Volume51,627
30 Day Avg. Volume45,406
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)8.88
Price to Sales (P/S)0.00
P/FCF Ratio8.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF83.50Price Target Upside53.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Basilea Pharmaceutica News
Bulls Say, Bears Say
Bulls Say
Funding SupportKey commitment from U.S. government agency provides crucial funding support for mid- and late-stage pipeline programs.
Market ApprovalThe FDA approval of Zevtera for specific indications makes it the only approved MRSA cephalosporin antibiotic for certain infections, giving it a unique market position.
Sales MilestoneCresemba continues to perform strongly, with sales in the Asia-Pacific region and China exceeding a pre-defined sales threshold, triggering a $2.5M milestone payment.
Bears Say
Clinical SetbacksRisks include setbacks with clinical-stage candidates, notably fosmanogepix.
Market Penetration ChallengesRisks include potential challenges in market penetration for ceftobiprole in the U.S. and setbacks with clinical-stage candidates like fosmanogepix.
Partnership RisksRisks include inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.96%
Mutual Funds
0.11% Other Institutional Investors
89.11% Public Companies and
Individual Investors
BSLN FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was CHF36.75 and its highest was CHF55.20 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is CHF663.60M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Aug 19, 2025 which is in 31 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Feb 18, 2025. The company reported CHF4.7 earnings per share for the quarter, beating the consensus estimate of CHF3.24 by CHF1.46.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 2.03.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,314,145 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of CHF4.7 in its last earnings report, beating expectations of CHF3.24. Following the earnings report the stock price went up 8.323%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in CH:BSLN
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
BSLN Stock 12 Month Forecast
Average Price Target
CHF83.50
▲(53.21%Upside)
Technical Analysis
Molecular Partners AG
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―